Contact

Get in touch

Dymista^®^ “can be considered the drug of choice”^1^ |For moderate/severe allergic rhinitis in patients 12 and over|

 

Adverse events should be reported.

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to MEDA:pv@medapharma.co.uk

1. Leung et al. MP29-02: A major advancement in the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129(5): 1216.